# ProVerum

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/proverum

- Industry: Medical Devices & Equipment
- Headquarters: Dublin, Ireland
- Website: www.proverummedical.com/
- Total disclosed funding: $118M
- Latest round: Series B (Aug 10, 2025)
- Investors on record: 11

## About

Based in Dublin, Ireland, ProVerum Limited develops innovative medical devices focused on relieving Lower Urinary Tract Symptoms (LUTS) stemming from Benign Prostatic Hyperplasia (BPH).ProVerum Limited specializes in creating medical devices designed to alleviate urinary symptoms caused by BPH. Founded in 2016 in Dublin, Ireland. In August 2025, ProVerum Limited raised EUR 68 million in series B funding led by new investor MVM Partners, with participation from other new investors OrbiMed Advisors and Ireland Strategic Investment Fund. Returning investors Gilde Healthcare, Lightstone Ventures, Atlantic Bridge, and Enterprise Ireland also participated in the round. The founder, Conor Harkin, has previously been involved in other ventures, further solidifying his expertise in the medical device field.ProVerum Medical specializes in innovative medical devices aimed at alleviating Lower Urinary Tract Symptoms (LUTS) caused by Benign Prostatic Hyperplasia (BPH). Their flagship product, the ProVee stent, features a unique 3-D geometry that mirrors the prostate's anatomy, aiding in effective, atraumatic de-obstruction of the prostatic urethra. The stent alleviates urinary symptoms with controlled radial force application, eliminating the need for surgical intervention. The ProVee delivery system is designed for compatibility with a low-profile flexible sheath, making it versatile for various clinical settings. ProVerum Medical primarily targets healthcare providers and urologists in markets including the United States, Canada, and Ireland, aiming to enhance patient outcomes for those with enlarged prostates.ProVerum Medical operates on a B2B model, generating revenue through direct sales of the ProVee stent and delivery systems to hospitals and urology clinics. This transaction structure may involve pricing that reflects the specialized nature of their products, with transactions occurring on a per-unit basis or through bundled partnerships with medical institutions, emphasizing the critical role of their technology in urological practices. The company's EBITDA for the most recent year, 2021, was EUR -4,097,937.50. The company plans to utilize the August 2025 funding to grow its operations and enhance its development initiatives.

## Funding rounds

- Series B, Aug 10, 2025, $79M — MVM Partners, OrbiMed Advisors, Gilde Healthcare, Ireland Strategic Investment Fund, Atlantic Bridge, Enterprise Ireland, Lightstone Ventures
- Series A, Jan 11, 2022, $34M — Gilde Healthcare, Atlantic Bridge, Lightstone Ventures
- Seed, May 3, 2018, $4.2M — Atlantic Bridge, Enterprise Ireland, Irrus Investments, Boole Investment Syndicate, Halo Business Angel Network, Xenium Capital

## Investors

- Atlantic Bridge (https://capitalatlas.ai/funds/atlantic-bridge) — Seed, Series A, Series B
- Enterprise Ireland (https://capitalatlas.ai/funds/enterprise-ireland) — Seed, Series B
- Irrus Investments — Seed
- Boole Investment Syndicate — Seed
- Halo Business Angel Network — Seed
- Xenium Capital (https://capitalatlas.ai/funds/xenium-capital) — Seed
- Gilde Healthcare (https://capitalatlas.ai/funds/gilde-healthcare) — Series A, Series B
- Lightstone Ventures (https://capitalatlas.ai/funds/lightstone-ventures) — Series A, Series B
- MVM Partners (https://capitalatlas.ai/funds/mvm-partners) — Series B
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B
- Ireland Strategic Investment Fund — Series B